{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:52:42Z","timestamp":1791247962434,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government","award":["Australian Government Research Training Scholarship"],"award-info":[{"award-number":["Australian Government Research Training Scholarship"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Contrary to reports on under-treatment in persons with Parkinson\u2019s disease, our study found similar anti-osteoporosis medication usage before and after their hip fractures among Finns with and without Parkinson\u2019s disease. Additional preventive measures may be needed to mitigate the high risk of hip fractures among persons with Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is associated with a doubled risk of hip fracture. However, previous reports suggest under-recognition of osteoporosis among persons with PD. Our study aimed to assess the annual prevalence of anti-osteoporosis medications among persons with and without PD in relation to diagnosis of PD and hip fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our nationwide matched cohort design included 33,153 persons diagnosed with incident PD between 2000 and 2009 in Finland and 1:2 matched comparison cohort. Persons with previous hip fractures were excluded. Annual prevalences of anti-osteoporosis medications were calculated for each year between 5 years before and 10 years after diagnosis of PD, and between 5 years before and 5 years after the incident hip fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prevalence of anti-osteoporosis medications was higher in persons with PD (3.62%, 95% confidence interval [CI] 3.28\u20133.98%) than those without PD (2.91%, 95% CI 2.70\u20133.14%), starting from 3 years before the diagnosis. Among individuals with incident hip fractures (1475 [13%] persons with PD and 1371 [6%] persons without PD), the annual prevalence were similar among persons with PD and without PD, peaking within 1 year after hip fractures (with PD: 20.3%, 95% CI 18.0\u201322.8%; without PD: 21.0%, 95% CI 18.5\u201323.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Contrary to reports on under-treatment in persons with PD, our study found similar anti-osteoporosis medication usage before and after their hip fractures among Finns with and without PD. Additional preventive measures, such as regular review of fall risk, is needed to mitigate the doubled risk of hip fracture in PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01780-z","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:49:07Z","timestamp":1791200947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-osteoporosis medications in persons with and without Parkinson disease in Finland"],"prefix":"10.1007","volume":"21","author":[{"given":"Miriam T. Y.","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Leena","family":"Lamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirpa","family":"Hartikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maija","family":"Tolppanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL, Nichols E, Alam T et al (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459\u2013480. https:\/\/doi.org\/10.1016\/S1474-4422(18)30499-X","journal-title":"Lancet Neurol"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E et al (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939\u2013953. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3","journal-title":"Lancet Neurol"},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s13760-023-02428-2","volume":"124","author":"A Murueta-Goyena","year":"2024","unstructured":"Murueta-Goyena A, Mui\u00f1o O, G\u00f3mez-Esteban JC (2024) Prognostic factors for falls in Parkinson\u2019s disease: a systematic review. Acta Neurol Belg 124:395\u2013406. https:\/\/doi.org\/10.1007\/s13760-023-02428-2","journal-title":"Acta Neurol Belg"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1002\/mdc3.13860","volume":"10","author":"R Camicioli","year":"2023","unstructured":"Camicioli R, Morris ME, Pieruccini-Faria F et al (2023) Prevention of falls in Parkinson\u2019s disease: guidelines and gaps. Mov Disord Clin Pract 10:1459\u20131469. https:\/\/doi.org\/10.1002\/mdc3.13860","journal-title":"Mov Disord Clin Pract"},{"key":"1780_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/jnnp-2013-307307","volume":"85","author":"KM Torsney","year":"2014","unstructured":"Torsney KM, Noyce AJ, Doherty KM et al (2014) Bone health in Parkinson\u2019s disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 85:1159\u20131166. https:\/\/doi.org\/10.1136\/jnnp-2013-307307","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.neurol.2020.07.015","volume":"177","author":"M Louvois","year":"2021","unstructured":"Louvois M, Ferrero S, Barnetche T et al (2021) High risk of osteoporotic fracture in Parkinson\u2019s disease: meta-analysis, pathophysiology and management. Revue Neurologique 177:660\u2013669. https:\/\/doi.org\/10.1016\/j.neurol.2020.07.015","journal-title":"Revue Neurologique"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"e1202","DOI":"10.1016\/j.wneu.2020.11.132","volume":"146","author":"B Liu","year":"2021","unstructured":"Liu B, Chen G, Yu Z et al (2021) Bone mineral density and related scores in Parkinson\u2019s disease: a systematic review and meta-analysis. World Neurosurg 146:e1202\u2013e1218. https:\/\/doi.org\/10.1016\/j.wneu.2020.11.132","journal-title":"World Neurosurg"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.parkreldis.2019.03.021","volume":"64","author":"EJ Henderson","year":"2019","unstructured":"Henderson EJ, Lyell V, Bhimjiyani A et al (2019) Management of fracture risk in Parkinson\u2019s: a revised algorithm and focused review of treatments. Parkinsonism Related Disord 64:181\u2013187. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.03.021","journal-title":"Parkinsonism Related Disord"},{"key":"1780_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116651","volume":"168","author":"M Schini","year":"2023","unstructured":"Schini M, Bhatia P, Shreef H et al (2023) Increased fracture risk in Parkinson\u2019s disease \u2013 An exploration of mechanisms and consequences for fracture prediction with FRAX. Bone 168: 116651. https:\/\/doi.org\/10.1016\/j.bone.2022.116651","journal-title":"Bone"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/ene.15782","volume":"30","author":"S Ilmaniemi","year":"2023","unstructured":"Ilmaniemi S, Tolppanen A, Herukka S et al (2023) Incidence and outcomes of head injuries in people with and without Parkinson disease. Euro J of Neurol 30:1648\u20131657. https:\/\/doi.org\/10.1111\/ene.15782","journal-title":"Euro J of Neurol"},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00198-025-07632-9","volume":"36","author":"MTY Leung","year":"2025","unstructured":"Leung MTY, Lamidi M-L, Tiihonen M et al (2025) Use of anti-osteoporosis medications in persons with and without Parkinson disease in Finland (pre-print). Osteoporos Int 36:1681\u20131690","journal-title":"Osteoporos Int"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181\u2013184. https:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12877-021-02145-6","volume":"21","author":"E Hentil\u00e4","year":"2021","unstructured":"Hentil\u00e4 E, Tiihonen M, Taipale H et al (2021) Incidence of antidepressant use among community dwellers with and without Parkinson\u2019s disease \u2013 a nationwide cohort study. BMC Geriatr 21:202. https:\/\/doi.org\/10.1186\/s12877-021-02145-6","journal-title":"BMC Geriatr"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2022.08.024","volume":"103","author":"S Lilja","year":"2022","unstructured":"Lilja S, Tolppanen A-M, Koponen M et al (2022) Incidence of antipsychotic use among community dwellers with and without Parkinson\u2019s disease. Parkinsonism Related Disord 103:69\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.024","journal-title":"Parkinsonism Related Disord"},{"key":"1780_CR15","unstructured":"European Medicines Agency (2012) Calcitonin - referral | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/calcitonin. Accessed 23 July 2026"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ejn.14269","volume":"49","author":"RN Rees","year":"2019","unstructured":"Rees RN, Noyce AJ, Schrag A (2019) The prodromes of Parkinson\u2019s disease. Eur J of Neurosci 49:320\u2013327. https:\/\/doi.org\/10.1111\/ejn.14269","journal-title":"Eur J of Neurosci"},{"key":"1780_CR17","unstructured":"Hip fracture. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Orthopaedic Society. Helsinki: The Finnish Medical Society Duodecim, 2017 (referred July 22, 2026). Available online at: www.kaypahoito.fi"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"e027049","DOI":"10.1136\/bmjopen-2018-027049","volume":"9","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049","journal-title":"BMJ Open"},{"key":"1780_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B et al (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093\u20132102. https:\/\/doi.org\/10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"key":"1780_CR20","unstructured":"Osteoporosis. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim, the Finnish Endocrine Society, the Finnish Society of Obstetrics and Gynaecology, and the Finnish Geriatricians. Helsinki: The Finnish Medical Society Duodecim, 2025 (referred July 22, 2026). Available online at: www.kaypahoito.fi"},{"key":"1780_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/jbmr.4821","volume":"38","author":"C Sing","year":"2023","unstructured":"Sing C, Lin T, Bartholomew S et al (2023) Global epidemiology of hip fractures: secular trends in incidence rate, post-fracture treatment, and all-cause mortality. J Bone Mineral Res 38:1064\u20131075. https:\/\/doi.org\/10.1002\/jbmr.4821","journal-title":"J Bone Mineral Res"},{"key":"1780_CR22","doi-asserted-by":"publisher","unstructured":"Patel R, Judge A, Johansen A, Javaid MK, Griffin XL, Chesser T, Griffin J, Marques EM (2024) Following hip fracture, hospital organizational factors associated with prescription of anti-osteoporosis medication on discharge, to address imminent refracture risk: a record-linkage study. J Bone Mineral Res zjae100. https:\/\/doi.org\/10.1093\/jbmr\/zjae100","DOI":"10.1093\/jbmr\/zjae100"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40520-024-02761-3","volume":"36","author":"D Gonz\u00e1lez-Quevedo","year":"2024","unstructured":"Gonz\u00e1lez-Quevedo D, Rubia-Ortega C, S\u00e1nchez-Delgado A et al (2024) Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients. Aging Clin Exp Res 36:103. https:\/\/doi.org\/10.1007\/s40520-024-02761-3","journal-title":"Aging Clin Exp Res"},{"key":"1780_CR24","doi-asserted-by":"publisher","unstructured":"Yoel U, Alkobi Weiss H, Goldbart A, Silverman Siris E, Fisher DL, Hassan L, Fraenkel M (2024) The impact of a fracture liaison service with in-hospital anti-osteoporosis treatment on subsequent hip fracture and mortality rates\u2014a single-center retrospective study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-024-07325-9","DOI":"10.1007\/s00198-024-07325-9"},{"key":"1780_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jama.2025.6003","volume":"334","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis: a review. JAMA 334:894. https:\/\/doi.org\/10.1001\/jama.2025.6003","journal-title":"JAMA"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01780-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01780-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01780-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:05:57Z","timestamp":1791245157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01780-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01780-z","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JSB has received grant funding or consulting funds from the National Health and Medical Research Council, Medical Research Future Fund, Victorian Government Department of Health and Human Services, Dementia Australia Research Foundation, Yulgilbar Foundation, Aged Care Quality and Safety Commission, Dementia Centre for Research Collaboration, Pharmaceutical Society of Australia, Society of Hospital Pharmacists of Australia, GlaxoSmithKline Supported Studies Programme, Amgen, and several aged care provider organizations unrelated to this work. All grants and consulting funds were paid to the employing institution. AMT acknowledges grants, paid through the institution of employment from Michael J Fox Foundation for Parkinson\u2019s research, Business Finland, European Regional Development Fund, Horizon EU and Amgen, unrelated to this work. MLL, MT, SH, and JPT declare that they have no conflicts of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}